Challenge in HTA for gene therapies

Last month, the Office of Health Economics published a report titled “Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?” I summarize some of the key challenges and solutions below. Challenge #1: Initial assessment of clinical effectiveness. Since gene therapies often target rare disease, the sample size from clinical trials is often…

All stocks are vaccine stocks

In a world with COVID-19, what factors are most influential to a company’s stock price? Are company specific or macroeconomic factors most important? It turns out, the speed of health care innovation in fighting COVID-19 may be the biggest single factor influencing all stock market prices. Barrons: General Electric stock was racing higher Tuesday, but…